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Bilayer Buccal Tablets of Furosemide: Design and Evaluation
Shardor Ambarish G*, S B Shirsand, Shailashri S Shirsand, Ganesh Keshavshetti, Anum Fatima, Sunil
Kumar Aute
ambarish.pharma@gmail.com

Abstract
Aim: In the present study, mucoadhesive bilayer buccal tablets of furosemide were fabricated with the objective
of avoiding first-pass metabolism and enhancing the bioavailability along with reducing the dosing frequency.
Methodology: Direct compression method was used to prepare bilayer buccal tablets of furosemide, with a
combination of polymers such as xanthan gum, karaya gum, and guar gum along with Carbopol 934-P and
ethylcellulose as the backing layer. In order to provide a unidirectional drug delivery to the mucosa and for drug
loss avoidance that occurs when there is a washout with saliva, the bilayer structure design was used. Physical
and biological parameters were measured for the designed tablets. Results: FXG1 formulation containing
xanthan gum, 1% and 2 % w/w of Carbopol 934p of matrix layer, and mannitol (15% w/w of matrix layer) used
as a channeling agent was found to be assuring. This formulation exhibited 82.98% drug release in 8 h along
with an acceptable strength of bioadhesion (5.40 g). Short-term stability studies on this formulation showed
that no significant changes in drug content and dissolution characteristics existed (p<0.05). IR spectroscopic
studies showed the absence of any drug-excipient interactions. The drug release was of zero order, whereas
the value for release exponent (n) ranged from 0.787 to 1.063 which demonstrated a diffusion control super case
II. Conclusion: The prepared buccal tablets of furosemide persisted in the buccal cavity longer, indicating that
mucoadhesive tablets of furosemide have a good potential for the treatment of edema and hypertension.
Key words: Bioadhesive strength, furosemide, Mucoadhesive buccal tablet, swelling index

Introduction
The oral route of drug delivery is perhaps the most
preferred method as compared to other routes, both
by clinicians and patients. Among the various routes
of drug delivery, drug delivery through transmucosal
routes (i.e., the nasal, oral, vaginal and rectal mucosa,
and ocular cavities) offers many benefits over peroral administration in case of systemic effect, but
also has drawbacks like degradation caused by
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gastrointestinal enzymes and first-pass metabolism.
Thus, there is rising interest in developing a
therapeutic agent utilizing transmucosal pathways
to deliver the drug to the right location in the body
and in proper quantity, so as to rapidly achieve and
sustain the appropriate concentration. As a result,
alternative absorptive mucosa is considered for drug
administration.1, 2
The buccal mucosa is rich in vascularization as
the jugular vein receives the blood flow directly.
Therefore, drug absorption through the buccal
mucosa bypasses the gastrointestinal route and
hepatic first-pass metabolism. Buccal cavity is
patient-friendly because of its easy accessibility
and application, together with the possibility of
terminating drug delivery in case of unexpected
side-effects and emergency.3, 4 Buccal tablets can
be formulated during the time of application to
maintain their position, retain shape, and integrity.
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They are also easily visible when treatment is going
on and the dosage can be controlled.5
The oral cavity is a potential site for drug delivery
because of its unique environment. The advantages
of this route are many. The drug is not exposed
to the stomach’s acidic pH. It is possible to reach
therapeutic drug concentration in the serum faster,
and without undergoing the first-pass metabolism,
the drug goes into the systemic circulation. The
mucous membrane forms the lining of the oral
cavity and the possibility of using it as a site for
drug absorption is very less explored.6
The oral mucosal surface contains a thin mucin film,
which might serve as a location for mucoadhesive
delivery for prolonged contact with the mucosa.
Additionally, the drug should be released towards
the mucosa in a unidirectional, predictable, and
controlled way to cause the necessary therapeutic
response. Usage of a bilayer device can provide
such a kind of unidirectional release. As a result, for
controlled or sustained drug delivery, the mucosal
surface of the oral cavity forms a potential site.
Furosemide is a broadly used “high-ceiling” loop
diuretics drug, used for chronic renal failure,
congestive heart failure, and hepatic cirrhosis.

Furosemide is weakly acidic (pKa 3.93), and
therefore its absorption occurs typically in the
stomach and upper portion of the small intestine.
After oral ingestion/administration, it is absorbed
incompletely,
rapidly
undergoes
first-pass
metabolism, giving a narrow absorption window
and low bioavailability (43-50%). Furosemide has a
biological half-life of 1-2 hours. The physiochemical
properties of furosemides and their low half-life
and molecular weight (330.7g/mol), make it an
ideal drug of choice for administration through the
buccal route. Hence, the aim of the present study is
to prepare and evaluate buccal tablets of furosemide
by the use of various bioadhesive polymers. This
will increase bioavailability and decrease the side
effects caused due to dosage and frequency of
administration. Such a dosage form is expected to
be retained for a longer time in the oral cavity and
provide sustained release, prolonging the absorption
phase and causing an increase in drug effect.7
In the present study, efficacious and prolonged
release mucoadhesive tablets of furosemide
using various polymers to surpass the first-pass
metabolism were designed in order to reduce dosing
frequency and to improve patient compliance with
improved bioavailability.

Table 1: Composition of buccal tablets of furosemide
FXG4

FKG0

FKG1

FKG2

FKG3

FKG4

FGG4

FXG3

FGG3

FXG2

FGG2

FXG1

FGG1

FXG0

Ingredients*
(mg/tablet)

FGG0

Formulation code

Furosemide
Carbopol934P
Xanthan Gum
Karaya Gum
Gaurgum
Mannitol
Aspartane
Mg. stearate
Flavour
MCC

10
--5
----15
3
2
2
63

10
2
1
----15
3
2
2
65

10
2
2
----15
3
2
2
64

10
2
3
----15
3
2
2
63

10
2
5
----15
3
2
2
61

10
----5
--15
3
2
2
63

10
2
--1
--15
3
2
2
65

10
2
--2
--15
3
2
2
64

10
2
--3
--15
3
2
2
63

10
2
--5
--15
3
2
2
61

10
2
----5
15
3
2
2
63

10
2
----1
15
3
2
2
65

10
2
----2
15
3
2
2
64

10
2
----3
15
3
2
2
63

10
2
----5
15
3
2
2
61

Ethyl cellulose

50

50

50

50

50

50

50

50

50

50

50

50

50

50

50

Total weight

150

150

150

150

150

150

150

150

150

150

150

150

150

150

150

*Weights expressed as mg per tablet;
FKG - formulation containing karaya gum as polymer
FGG - formulation containing guar gum as polymer 		

FXG - formulation containing xanthan gum as polymer
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Materials
Furosemide was gifted by Geno Pharmaceuticals
Ltd, Mapusa, Goa. Ethyl cellulose was obtained as
a gift from Loba Chemie Pvt Ltd, Mumbai, India;
karaya gum and guar gum was gifted by Nutriroma
Pvt Ltd, Hyderabad; xanthan gum was obtained as
a gift from Panchi Chemicals Pvt Ltd, Mumbai; and
Carbopol 934p was gifted by Alkem Labs Pvt, Ltd,
Mumbai. All other materials used were of analytical
or pharmacopoeial grade.

Methods
Preparation of the buccal tablets 8-9
Preparation method: Direct compression method
was used for the preparation of buccal tablets of
furosemide by using xanthan gum, karaya gum, guar
gum, and Carbopol 934p as polymers.
Procedure for preparation: The constituents for the
formulation, namely furosemide, polymer, and
other excipients were weighed accurately (Table 1).
Furosemide was mixed with mannitol thoroughly
on butter paper. Next, the rest of the ingredients,
apart from the lubricant, were mixed from low to
high weights in order and blended in an inflated
polyethylene pouch for 10 min. Next, after the
addition of lubricant, mixing was carried on for
another two minutes. The blend thus formed (100
mg) was pre-compressed in a 10-station rotary tablet
punching machine (Clit, Ahmedabad) at a pressure
of 0.5 ton and turret speed of 2 rpm in order to form
a flat-faced tablet of a single layer of 7 mm diameter.
Then, a pressure of 3.5 tons and turret speed of 2
rpm, after the addition of 50 mg of ethyl cellulose
powder, was carried out for the final compression to
form the bilayer tablet.

determine the weight variation. Monsanto hardness
tester was used to determine hardness and the
friability was determined using Roche friabilator.
In order to carry out the drug content uniformity
test, five tablets were weighed and powdered. A
powder equivalent to 10 mg of drug was extracted
in methanol, filtered using 1.5 µm membrane filter
disc (Whatsman No 1 filter paper), and analyzed
by measuring the absorbance at 233.6 nm against
solvent blank after appropriate dilutions were
prepared. Using the standard calibration curve, the
amount of furosemide present was found out. The
% drug content was determined as a mean of three
measurements.
For the determination of the surface pH of the
buccal tablets, a combined glass electrode was used.
Swelling of the tablet was carried out for 2 h at
room temperature by keeping it in contact with 6
ml of distilled water (pH 6.8±0.05). The pH was
measured by placing the electrode onto the surface
of the tablet and equilibrating for 1 min.10 (Fig.1).
The swelling index11,12 of the buccal tablet was
calculated using phosphate buffer pH 6.8. The initial
weight of the tablet was measured (w1). Then, it was
placed in a petri-dish containing pH 6.8 phosphate
buffer (6 ml) kept at 37±1°C in an incubator, The
tablet was taken out at different time points (0.5, 1.0
to 9.0 h), and weighed again (w2) (Fig.2). Then, the
swelling index was calculated by using the formula
below:
Swelling index = 100 (w2-w1)/w1.

Evaluation of buccal tablets
Evaluation of the tablets was carried out by
measurement of the following: variation in weight,
hardness, friability, drug content uniformity,
swelling index, surface pH, ex vivo mucoadhesive
strength, in-vitro drug release, short-term stability
(IR spectroscopy), and drug-excipient interaction.
Fifteen tablets were randomly selected and each
was weighed separately. The weight of each tablet
was compared with the average weight in order to

26
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Fig 1: pH examination of buccal tablets using glass
electrode
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filter disc (Millipore Corporation) and analyzed for
furosemide after appropriate dilution and measured
at 274.50 nm.

Fig 2: Swelling index study of formulation FXG1
Mucoadhesion strength13-16
In the laboratory, the instrument used for measuring
bioadhesion was assembled. Mucoadhesion strength
of the tablet was calculated by a modified physical
balance by the procedure reported by Gupta et al.15
whereas, a mucosal model, bovine cheek pouch was
used (Buccal mucosa was collected from the local
slaughterhouse).(Fig.3).

Fig 3: Bioadhesion testing apparatus
In vitro drug release study17-18
For the study, USP XXIII tablet dissolution test
apparatus-II (Electrolab TDT-06N) was used, with
50 rpm paddle and for dissolution medium 200 ml
of pH 6.8 phosphate buffer was used. The release
study was performed at a temperature of 37±0.5°C.
The tablet’s backing layer is attached to a glass disk
having cyanoacrylate adhesive. The disk is kept in
the dissolution vessel at the bottom. Samples (5
ml each) are taken at fixed time intervals and are
replaced with an equal volume of fresh medium. The
samples were filtered through 0.45 µm membrane

Stability studies
To perform the accelerated stability studies,
the following criteria were maintained: 40±2°C
temperature / 75±5% relative humidity for a
duration of 90 days. An adequate number of tablets
(formulations FXG1, 15 nos.) were kept in vials of
amber colour with rubber stoppers. These were then
placed in a stability chamber which was maintained
at 40±2°C/75± 5% RH. Samples were taken at
one-month interval and analyzed for the drug
content. After 90 days, the drug release profile was
determined by dissolution test.
Drug-excipient interaction studies
Drug-excipient interactions were ruled out by IR
spectroscopy studies on the samples (FSA3, FXG3,
FKG3, FGG3) stored for three months at 40±2°C
/ 75±5% RH. The IR spectrum of the pure drug
furosemide displayed characteristic peaks at 31203400cm-1, 1593cm-1, 1323cm-1, 580cm-1, 1408cm-1 due
to C-H (aromatic), C-H (aliphatic), C-H bending (in
plane), C-H bending (out of plane), C-CL and S=O
groups, respectively. All the above characteristic
peaks of the pure drug were also found in the IR
spectrum of the formulation FSA3 (peaks at 3123.00
cm-1, 1670.41 cm-1, 1593.25 cm-1, 1321.28 cm-1, 580
cm-1 and 1402.00 cm-1, FXG3 (peaks at 3126.00 cm-1,
1672.34 cm-1, 1593.25 cm-1, 1323.21 cm-1, 583 cm-1
and 1402.00 cm-1) FKG3 (peaks at 3122.00 cm-1,
1672.34 cm-1, 1593.25 cm-1, 1323.21 cm-1, 582 cm-1
and 1402.00 cm-1) and FGG3 (peaks at 3124.00 cm1
, 1672.34 cm-1, 1593.25 cm-1, 1323.21 cm-1, 580.59
cm-1 and 1402.00 cm-1) due to C-H (aromatic), C-H
(aliphatic), C-H bending (in plane), C-H bending (out
of plane), C-CL and S=O groups respectively. The
presence of the above peaks indicates the undisturbed
structure of the drug in the above formulation.
Hence, there are no drug-excipient interactions.
IR spectra of furosemide (pure drug), FSA3, FXG3
FKG3, FGG3 along with other excipients are shown
in figure 8 to 12.

Results and discussion
The main objective of the present work was to
produce buccoadhesive bilayer tablets of furosemide,
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an antidiuretic (Na-K-2Cl symporter), comprising
of a non-adhesive protective layer that is free of
drug. The double-layered structure was expected to
- i) provide unidirectional drug delivery, ii) prevent
drug loss due to saliva washout, iii) immediately
release the drug to produce a rapid pharmacological
effect and iv) provide sustained drug release over
a prolonged period of time. A total of fifteen
formulations of buccoadhesive bilayer tablets of
furosemide were prepared and their evaluations were
carried out for physical, biological, and mechanical
parameters. According to the work plan, the
tablets were evaluated for their thickness, hardness,
friability, weight variation, swelling index, surface
pH, drug content, and mucoadhesive strength. The
buccoadhesive tablets were uniform and smooth in
appearance on physical examination. The hardness
was found to be 3.76 to 4.67 kg/cm2; hardness
increases with increasing Carbopol 934p proportion
in the formulation. As shown by the minimum value
of standard deviation, the variance in the thickness
and weight were found to be uniform (3.21 to 3.37
mm and 148.49 to 150.46 mg respectively). In order
to withstand the rigours of handling and transport,
friability values below 1% imply strong mechanical
strength, the results of which are given in Table 2.
It shows that the drug content of tablets was quite
uniform, and on an average, the drug content was

within 98.56% to 100.97 %. The standard deviation
and coefficient of variation were found to be low
(<1, not shown in the table) which shows that there
was a uniform distribution of furosemide within
the buccoadhesive tablets. The surface pH of all the
tablets was within a range of 5.88 to 6.94 (Table
2) which was close to neutral pH. Hence, it can be
understood that the prepared tablets will be nonirritant in the mouth. The swelling profile of the
prepared formulations is shown in Table 2. It has
been previously reported that the polymer’s swelling
state is critical for its bioadhesive behaviour.
Adhesion takes place soon after swelling begins,
although there is not a very tight bond between the
mucosal layer and the polymer. With the amount of
hydration, the adhesion can increase to a point where
over-hydration leads to an unexpected decrease in
adhesive strength due to disentanglement at the
interface between polymer and tissue. The obtained
results indicate that with increase in the Carbopol
934P concentration, the swelling index increases.
The highest mucoadhesive strength was obtained
for FXG4, i.e., 7.88 gm. The reason for this might be
a strong electrostatic interaction between opposite
charges on the surface of Carbopol 934P and
mucous membrane which are positive and negative,
respectively.

Table 2: Evaluation parameters of buccal tablets of furosemide
Formulation
code

Mean
Hardness*
(kg/cm2±
SD)

Mean
Thickness*
(mm± SD)

FXG0

3.76±0.02

FXG1

Swelling
Index after
8 h* (Mean
±SD)

Mucoadhesive
Strength*
(gm)
(Mean±SD)

Friability
(%±SD)

3.30±0.015

149.37±0.57

0.96±0.015

98.70±1.05

6.17±0.05

28.17±5.43

4.19±0.16

4.13± 0.15

3.25±0.030

150.28±0.10

0.94±0.05

99.29±0.75

6.53±0.05

59.59±4.95

5.40±0.13

FXG2

4.29±0.01

3.28±0.02

149.28±0.13

0.49±0.03

100.26±0.75

6.67±0.05

73.08±4.28

6.59±0.42

FXG3

4.32±0.02

3.37±0.11

150.18±0.07

0.27±0.05

98.60±0.92

6.74±0.7

85.24±4.08

7.35±0.19

FXG4

4.38±0.02

3.30±0.015

150.46±0.20

0.59±0.05

99.28±1.10

6.94±0.10

99.65±4.77

7.88±0.105

FKG0

3.87±0.02

3.24±0.015

148.49 ±0.52

0.84±0.04

98.56 ±0.96

5.88± 0.09 38.80±5.38

4.22±0.12

FKG1

4.17± 0.01

3.28±0.015

150.28 ±0.15

0.72±0.04

98.58 ±1.14

6.19±0.05

59.67± 4.61

5.57±0.10

FKG2

4.28±0.02

3.29±0.01

148.51 ±1.01

0.62±0.045

100.03±0.56

6.27± 0.05 76.83± 5.06

6.63±0.13

FKG3

4.40±0.02

3.28±0.02

150.25 ±0.10

0.62±0.045

99.64 ±1.30

5.94±0.04

83.24± 4.89

7.34±0.13

FKG4

4.65±0.01

3.32±0.032

150.07±0.05

0.60±0.05

100.10±0.46

6.63±0.05

98.81±5.49

7.74±0.16
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Drug
Content*
(Mean±SD)

Surface
PH*
(Mean
±SD)

Mean Weight
Variation*
(mg± SD)
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Formulation
code

Mean
Hardness*
(kg/cm2±
SD)

Mean
Thickness*
(mm± SD)

FGG0

3.86±0.01

3.21±0.01

149.47±0.47

FGG1

4.15±0.01

3.24±0.04

FGG2

4.20±0.01

FGG3
FGG4

Mean Weight
Variation*
(mg± SD)

Friability
(%±SD)

0.82±0.05

Drug
Content*
(Mean±SD)

Surface
PH*
(Mean
±SD)

Swelling
Index after
8 h* (Mean
±SD)

Mucoadhesive
Strength*
(gm)
(Mean±SD)

99.56±0.83

6.41±0.05

39.19±5.00

3.79±0.22

150.16±0.076 0.75±0.06

100.25±0.24

5.96±0.04

68.5±5.55

5.60±0.43

3.25±0.03

150.18±0.070 0.60±0.03

100.56±0.64

6.20±0.04

83.54±3.39

6.28±0.14

4.39±0.01

3.24±0.015

149.63±0.38

0.69±0.04

100.97±0.025

5.96±0.06

96.31±2.69

7.29±0.12

4.67±0.10

3.29±0.01

149.18±0.07

0.63±0.05

100.96±0.04

6.26±0.06

123.16±3.99

7.79±0.14

*Average of three determinations

In vitro drug release: It can be well understood from
the dissolution data that the developed formulations
have released more than 82.98% drug in 8 h. The
formulation FXG1 (containing xanthan gum 1% and
2% w/w of Carbopol 934p), and mannitol (15% w/w
of matrix layer) was assuring, having t25%, t50%
and t70% values of 2.1, 4.1 and 6.25 h, respectively
and released 82.98% drug within 8 h. Results are
tabulated (Table 3) and the drug release profiles
have been shown in figures 4, 5, and 6. A comparison
of the release parameters is shown in figure 7.

case II transport mechanism (having ‘n’ values from
0.787 to 1.063).
Pure Furosemide in its IR spectrum showed
characteristic peaks at 3400 cm-1 and 1664 cm-1
due to C-NH (aromatic) and C-H (aliphatic) groups,
respectively. The spectra also showed peaks of 1593
cm-1 and 1323 cm-1 which were characteristic of
-NH2 and -SO2 groups, peaks at 580 cm-1 and
1408cm-1 are due to –Cl and S=O, respectively. All
of these characteristics appeared in the IR spectrum
of FXG3 (3122 cm-1 and 1672.34 cm-1 due to -NH
and C-H stretching respectively and peaks at 1593.25
cm-1 and 1323.21 cm-1 are due to –NH2 bending
and SO2 groups, peaks at 583 cm-1 and 1402 cm-1
are due to –Cl and S=O, respectively). From the IR
data, we can say that the structure of furosemide
was undisturbed in the prepared formulation.
The stability studies indicate that the drug content
of FXG1 did not show any significant alteration at
40±2 0C / 75±5% RH after it was stored for 90 days.
The value of ‘t’ was found to be 1.978 (p< 0.05).

Drug release kinetics: The data obtained from in
vitro drug release from buccoadhesive tablets of
furosemide was analyzed by linear regression for
the goodness of fit test according to zero and first
kinetics and according to Higuchi’s and Peppas
models to understand the drug release mechanism.
It is evident from the results that all the tablets
showed drug release through zero order kinetics
(having ‘r’ values from 0.987 to 0.999). Data from
the Higuchi and Peppas models reveal that the drug
release occurred through diffusion control super
Table 3: Dissolution parameters of the formulations
Sl. No.
1
2
3
4
5
6
7
8
9

Formulation
code
FXG0
FXG1
FXG2
FXG3
FXG4
FKG0
FKG1
FKG2
FKG3

t25% (h)

t50% (h)

t70% (h)

Cumulative % drug release in 8 h

2.90
2.1
2.25
3.25
4.25
3.25
2.4
2.3
3.25

5.8
4.1
4.80
6.2
7.7
6.3
4.2
5.4
6.3

7.55
6.25
6.45
>8
>8
>8
6.4
7.25
>8

71.53
82.98
77.35
68.27
57.60
68.27
81.33
75.01
63.88
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Sl. No.

Formulation
code

t25% (h)

t50% (h)

t70% (h)

Cumulative % drug release in 8 h

10
11
12
13
14
15

FKG4
FGG0
FGG1
FGG2
FGG3
FGG4

4.2
3.3
2.65
2.55
2.8
3.95

7.59
6.6
4.6
4.7
5.45
7.9

>8
>8
6.9
7.5
>8
>8

52.66
63.88
81.11
74.64
63.88
51.33

Fig 4: Cumulative percent drug released Vs time plots
(zero order) of formulations FXG0, FXG1, FXG2, FXG3
and FXG4

Fig 5: Cumulative percent drug released Vs time plots
(zero order) of formulations FKG0, FKG1, FKG2, FKG3
and FKG4

Fig 6: Cumulative percent drug released Vs time plots
(zero order) of formulations FGG0, FGG1, FGG2, FGG3
and FGG4

Fig 8: IR spectrum of furosemide

Fig 7: Comparison of dissolution parameters (t25%, t50% and t70%) of buccal tablets of furosemide
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Fig 9: IR spectrum of promising formulation FSA3

Fig 10: IR spectrum of promising formulation FXG3

Fig 11: IR spectrum of promising formulation KKG3

Fig 12: IR spectrum of promising formulation FGG3

Conclusion
The outcomes of this study indicate that
buccoadhesive bilayer tablets of furosemide with
controlled drug release can be successfully prepared
by direct compression method using xanthan
gum, karaya gum, guar gum, and Carbopol 934p
as mucoadhesive polymers and ethyl cellulose as
a backing layer. It exhibited well-controlled and
delayed release pattern. This study concludes that
the addition of Carbopol 934p increases the viscosity
and swelling of tablets which in turn controls
the drug release and improves its mucoadhesive
properties. The formulation FXG1 (containing
xanthan gum 1% and 2% w/w of Carbopol 934p of
matrix layer), Carbopol 934p (2% w/w of matrix
layer), and mannitol (channeling agent, 15% w/w of
matrix layer) were promising. It showed an in vitro
drug release of 82.98% in 8 h and an acceptable
bioadhesion strength (5.40 g).
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